BioSpace News Archive

Drug Development

Catalyst Biosciences Initiates Phase II/III Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B With Inhibitors

This Phase 2 open-label, subcutaneous efficacy trial in individuals with hemophilia A or B with inhibitors will evaluate the ability of MarzAA to eliminate, or minimize, spontaneous bleeding episodes.

January 4, 2018
·
4 min read
Drug Development

Auris Medical Provides Update on AM-111 Development Program

Further analyses on the basis of the full data set provide additional confirmation of and support for AM-111’s otoprotective effects in the profound acute hearing loss subpopulation.

January 4, 2018
·
7 min read
Policy

The FDA Fast Tracks 60 Degrees Pharma’s Malaria Drug

The company submitted the NDA in December.

January 4, 2018
·
4 min read
Pharm Country

Envigo Allocates $300M Term Loan B Facility

J.P. Morgan is serving as the administrative agent for the refinancing and joint bookrunners are J.P. Morgan, SunTrust Robinson Humphrey and Barclays.

January 4, 2018
·
7 min read
Zora Announces CERT - A Validated Test for Cardiovascular and Diabetes Risk Prediction

Zora announces the expansion of its Coronary Event Risk Test to include prediction of type II diabetes.

January 4, 2018
·
4 min read
Biotech Beach

CURE Pharmaceutical Launches New Brand Focused on Patient Needs in Medication Delivery

CURE’s proprietary CUREfilm technology platform optimizes drug delivery for better patient outcomes and experiences.

January 4, 2018
·
3 min read
Business

Sigilon Therapeutics Appoints David E. Moller, M.D., as CSO

Dr. Moller brings a long history of experience in drug discovery and development to the company, including a focus on development of therapeutics for metabolic disorders and in the identification and evaluation of emerging technologies.

January 4, 2018
·
3 min read
Toshiba Medical Systems Officially Becomes Canon Medical Systems

Canon announced that the change of the company name enters into effect today.

January 4, 2018
·
3 min read
Pharm Country

LIU Brooklyn’s New Study Finds Swearing Aloud Boosts Physical Performance

A groundbreaking new study published in the Journal of Psychology of Sports and Exercise has found that swearing aloud can increase physical performance, strength, and power associated with exercise.

January 4, 2018
·
2 min read
ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies

Lack of PMN310 binding to perivascular amyloid plaque in Alzheimer’s brain tissue may eliminate dose-limiting brain swelling seen with aducanumab.

January 4, 2018
·
4 min read